Liraglutide the Novo Nordisk’s experimental type 2 diabetes drug is proved to control the blood sugar better. In a 26 week long head to head trial this Danish company finds that the patients given the liraglutide once a day have received a reduction of 1.1 percent in HCA1c levels, a key ingredient in blood sugar. Thus the drug works a step ahead of the other drug Byetta that has recorded less than 0.8% reduction in the blood sugar. Nearly 55% of the liraglutide patients reached the ADA target compared with close to 45 percent on Byetta, known chemically as exenatide. The company Novo Nordisk is looking forward to European and American approval next month.
Thomas Russo, an analyst with the Robert W. Baird says the comparative data is very relevant in the competitive scenario. As liraglutide is an oral drug, the greatest challenge will be to convene people to opt for oral drug instead of injection. It can be added that both liraglutide and Byetta belong to the GLP-1 class.
In the 26 week long study, the patients have lost up to 3 kgs.of weight. Thus the drug is desirable for obesity which is yet another cause of diabetes. Some earlier drugs have been reported to be responsible for weight gain.
On the other hand, the danger of hypoglycemia, dangerously low blood sugar, is significantly lower in the liraglutide group. Weight loss and no risk of hypoglycemia is expected to be helpful for the patients.
Source: THE GUARDIAN